BeyondSpring's Next Move Uncertain After Plinabulin CRL
Limited Impact On China Partner Hengrui?
Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.
You may also be interested in...
Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma.
Hengrui’s second major in-licensing deal this year is the latest example of the Chinese pharma innovation darling’s eagerness for new assets, particularly as some of its other products come under pressure.
A rare disclosure by China’s national health insurance payer shows how a major state-owned drug maker used its market-dominating position to dodge price-lowering schemes and increase drug prices more than 10-fold.